Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Abvc Biopharma Inc (NQ: ABVC ) 0.5265 -0.0159 (-2.93%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 69,056 Open 0.5400 Bid (Size) 0.5052 (13) Ask (Size) 0.5380 (1) Prev. Close 0.5424 Today's Range 0.5200 - 0.5800 52wk Range 0.4053 - 2.450 Shares Outstanding 24,420,526 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 12 Health Care Stocks Moving In Tuesday's After-Market Session October 29, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session October 16, 2024 Via Benzinga Performance YTD -56.12% -56.12% 1 Month +10.94% +10.94% 3 Month -23.34% -23.34% 6 Month -50.79% -50.79% 1 Year -50.33% -50.33% More News Read More 12 Health Care Stocks Moving In Tuesday's After-Market Session October 15, 2024 Via Benzinga ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements August 15, 2024 Via NewMediaWire Topics Intellectual Property Exposures Intellectual Property Product Safety ABVC Stock Earnings: ABVC BioPharma Reported Results for Q2 2024 August 14, 2024 Via InvestorPlace ABVC Stock Earnings: ABVC BioPharma Reported Results for Q1 2024 May 17, 2024 Via InvestorPlace ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI July 09, 2024 Via NewMediaWire ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals July 02, 2024 Via NewMediaWire ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals July 02, 2024 Via TheNewswire.com ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market June 25, 2024 Via NewMediaWire Topics Intellectual Property Exposures Intellectual Property ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue June 12, 2024 Via NewMediaWire Immunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M May 24, 2024 Via NewMediaWire ABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24M May 22, 2024 Via NewMediaWire Promising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M May 15, 2024 Via NewMediaWire Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M May 09, 2024 Via NewMediaWire Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M May 09, 2024 Via TheNewswire.com Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket April 24, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's After-Market Session April 23, 2024 Via Benzinga AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share April 18, 2024 Via TheNewswire.com Topics Artificial Intelligence Exposures Artificial Intelligence AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share April 18, 2024 Via NewMediaWire Topics Artificial Intelligence Exposures Artificial Intelligence ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M April 17, 2024 Via NewMediaWire 12 Health Care Stocks Moving In Wednesday's After-Market Session April 10, 2024 Via Benzinga ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M April 10, 2024 Via NewMediaWire ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M April 10, 2024 Via TheNewswire.com 12 Health Care Stocks Moving In Monday's After-Market Session April 01, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
